Protopic (Tacrolimus) ointment

Protopic, which contains the active ingredient tacrolimus, is a prominent dermatological treatment used for atopic dermatitis. It was originally developed by the Japanese pharmaceutical company Fujisawa Pharmaceutical Co., Ltd. (which later merged to become Astellas Pharma). In a significant strategic shift, Astellas Pharma transferred the global rights for Protopic to LEO Pharma, a Danish company specializing in medical dermatology.

Today, the product is manufactured at LEO Pharma's specialized facilities, most notably in Dublin, Ireland, which serves as a global hub for their topical products. The ultimate ownership lies with LEO Pharma A/S, which is headquartered in Ballerup, Denmark. The company is primarily owned by the LEO Foundation, ensuring a focus on long-term research and development in the field of skin health.